Table 1.
Baseline clinical and disease characteristics
| GEJCa | GCa | |||
|---|---|---|---|---|
| FTD/TPI | Placebo | FTD/TPI | Placebo | |
| (n = 98) | (n = 47) | (n = 239) | (n = 121) | |
| Age, years | ||||
| Mean | 61 | 62 | 63.4 | 61.9 |
| Median (range) | 62.0 (24–89) | 62.0 (42–80) | 64 (27–86) | 63 (32–82) |
| Sex, n (%) | ||||
| Male | 83 (85) | 40 (85) | 169 (71) | 76 (63) |
| Race, n (%) | ||||
| White | 83 (85) | 37 (79) | 161 (67) | 74 (61) |
| Asian | 6 (6) | 4 (9) | 45 (19) | 25 (21) |
| Black | 0 | 0 | 1 (< 1) | 2 (2) |
| Not collected | 8 (8) | 4 (9) | 30 (13) | 20 (17) |
| Other | 1 (1) | 2 (4) | 2 (1) | 0 |
| ECOG PS, n (%) | ||||
| 0 | 28 (29) | 15 (32) | 95 (40) | 53 (44) |
| 1 | 70 (71) | 32 (68) | 144 (60) | 68 (56) |
| Geographic region, n (%) | ||||
| Japan | 6 (6) | 4 (9) | 40 (17) | 23 (19) |
| USA | 13 (13) | 3 (6) | 8 (3) | 2 (2) |
| EU | 79 (81) | 40 (85) | 191 (80) | 96 (79) |
| Previous gastrectomy, n (%) | ||||
| Yes | 39 (40) | 26 (55) | 108 (45) | 156 (40) |
| No | 59 (60) | 21 (45) | 131 (55 | 73 (60) |
| Prior radiotherapy, n (%) | ||||
| Yes | 36 (37) | 17 (36) | 35 (15) | 9 (7) |
| No | 62 (63) | 30 (64) | 204 (85) | 112 (93) |
| Number of metastatic sites, n (%) | ||||
| 1–2 | 50 (52) | 25 (53) | 105 (44) | 47 (39) |
| ≥ 3 | 48 (49) | 22 (47) | 134 (56) | 74 (61) |
| Number of prior regimens, n (%) | ||||
| 2 | 25 (26) | 16 (34) | 101 (42) | 47 (39) |
| 3 | 41 (42) | 15 (32) | 93 (39) | 45 (37) |
| ≥ 4 | 32 (33) | 16 (34) | 45 (19) | 29 (24) |
EU Europe, FTD/TPI trifluridine/tipiracil, GEJC gastroesophageal junction cancer, GC gastric cancer, USA United States of America
aTwo patients had both gastric and GEJC tumors and were excluded from this analysis